Journal of Pharmacology and

Lipinski, C.A. (2000) Drug-like Properties of Poor Solubility and Poor Permeability. Journal of Pharmacological and Toxicological Methods, 44(1), 235-249. 

Zhang, Y. and Wells, J., The effects of chronic caffeine administration on peripheral adenosine receptors, Journal of Pharmacology and Experimental Therapeutics, 254, 757, 1990. 

Rush, C., Sullivan, J. and Griffiths, R., Intravenous caffeine in stimulant drug abusers Subjective reports and physiological effects. Journal of Pharmacology and Experimental Therapeutics 273(1), 351-358, 1995. 

Lauver DA, Lockwood SF, and Lucchesi BR. 2005. Disodium disuccinate astaxanthin (Cardax) attenuates complement activation and reduces myocardial injury following ischemia/reperfusion. Journal of Pharmacology and Experimental Therapeutics 314(2) 686-692. 

Cunningham, M. 2000. Genomics and proteomics, the new millennium of drug discovery and development. Journal of Pharmacological and Toxicological Methods 44(1), 291-300. 

Zeng, H., Lozinskaya, I.M., Lin, Z., Willette, R.N., Brooks, D.P. and Xu, X. (2006) Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator. The Journal of Pharmacology and Experimental Therapeutics, 319, 957-962. 

Nau, C., Seaver, M., Wang, S.Y. and Wang, G.K. (2000) Block of human heart hHl sodium channels by amitriptyline. The Journal of Pharmacology and Experimental Therapeutics, 292. 1015-1023. 

A. M. (2005) HERG-Lite a novel comprehensive high-throughput screen for drug-induced hERG risk. Journal of Pharmacological and Toxicological Methods, 52, 136-145. 

Anantharam, A., Markowitz, S.M. and Abbott, G.W. (2003) Pharmacogenetic considerations in diseases of cardiac ion channels. The Journal of Pharmacology and Experimental Therapeutics, 307, 831-838. 

Hamlin, R.L., Cruze, C.A., Mittelstadt, S. W., Kijtawomrat, A., Keene, B.W., Roche, B.M., Nakayama, T., Nakayama, H., Hamlin, D.M. and Arnold, T. (2004) Sensitivity and specificity of isolated perfused guinea pig heart to test for drug-induced lengthening of QTc. Journal of Pharmacological and Toxicological Methods, 49, 15—23. 

Hanson, L.A., Bass, A.S., Gintant, G., Mittelstadt, S., Rampe, D. and Thomas, K. (2006) ILSI-HESI cardiovascular safety subcommittee initiative evaluation of three non-clinical models of QT prolongation. Journal of Pharmacological and Toxicological Methods, 54, 116—129. 

Gralinski, M.R. (2000) The assessment of potential for QT interval prolongation with new pharmaceuticals impact on drug development Journal of Pharmacological and Toxicological Methods, 43, 91-99. 

Ekins, S., Crumb, W.J., Sarazan, R.D., Wikel, J.H. and Wrighton, S.A. (2002) Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. The Journal of Pharmacology and Experimental Therapeutics, 301, 427—434. 

H, X.Q., Bjorkman, A., Andersson, T.B., Ridderstrom, M. and Masimirembwa, C.M. (2002) Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2 C8 a new high affinity and turnover enzyme-specific probe substrate. Journal of Pharmacology and Experimental Therapeutics, 300 (2), 399-407. 

Thummel, K.E., Shen, D.D., Podoll,T.D., Kunze, K.L., Trager, W.F., Bacchi, C.E., Marsh, C.L., McVicar, J.P., Barr, D.M., Perkins, J.D., Carithers, R.L. (1994) Use of midazolam as a human cytochrome P450 3A probe. II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. Journal of Pharmacology and Experimental Therapeutics, 271 (1), 557-566. 

Sutton, D., Butler, A.M., Nadin, L. and Murray, M. (1997) Role of CYP3A4 in human hepatic diltiazem N-demethylation inhibition of CYP3A4 activity by oxidized diltiazem metabolites. Journal of Pharmacology and Experimental Therapeutics, 282 (1), 294-300. 

Ernest, C.S., II, Hall, S.D. and Jones, D. R. (2005) Mechanism-based inactivation of CYP3A by HIV protease inhibitors. Journal of Pharmacology and Experimental Therapeutics, 312 (2), 583-591. 

B. K. (1967) Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration. British Journal of Pharmacology and Chemotherapy, 29, 150. 

C. M. Jr. (1972) Physiological disposition of fenprofen in man. III. Metabolism and protein binding of phenprofen. Journal of Pharmacology and Experimental Therapeutics, 183, 449. 

Sitar, D.S. and Thornhill, D.P. (1973) Methimazole absorption, metabolism and excretion in the albino rat. Journal of Pharmacology and Experimental Therapeutics, 184, 432. 

Mills, J.B., Rose, K.A., Sadagopan, N., Sahi, J. and de Morais, S.M. (2004) Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. The Journal of Pharmacology and Experimented Therapeutics, 309, 303-309. 

Egnell, A.-C., Houston, B. and Boyer, S. (2003) in vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. The Journal of Pharmacology and Experimental Therapeutics, 305, 1251-1262. 

Gao, B., Hagenbuch, B., Kullak-Ublick, G.A., Benke, D., Aguzzi, A. and Meier, P. J. (2000) Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. Journal of Pharmacology and Experimental Therapeutics, 294, 73-79. 

---